Research indicates that GCG excess, rather than insulin deficiency, is crucial for diabetes pathogenesis
One such innovation is Zepbound (Tirzepatide), a prescription medication designed to aid in weight loss for individuals struggling with obesity or overweight-related health issues
The case studies were conducted using Claude 3.7 Sonnet for the retrosynthetic pathway generation, while the metadata prediction was performed using Claude 3 Opus
[DOI] [PubMed] [Google Scholar] 11.Doessing S., Heinemeier K.M., Holm L., Mackey A.L., Schjerling P., Rennie M., Smith K., Reitelseder S., Kappelgaard A.M., Rasmussen M.H., et al
If the FDA finalizes its April 30, 2026 proposal to exclude semaglutide and tirzepatide from the 503B Bulks List, large-scale 503B compounding of those medications would no longer be legally permissible